Clot waveform of APTT has abnormal patterns in subjects with COVID-19

[1]  J. Low,et al.  Clinical and laboratory features of hypercoagulability in COVID-19 and other respiratory viral infections amongst predominantly younger adults with few comorbidities , 2021, Scientific Reports.

[2]  F. Andreotti,et al.  Marked von Willebrand factor and factor VIII elevations in severe acute respiratory syndrome coronavirus-2-positive, but not severe acute respiratory syndrome coronavirus-2-negative, pneumonia: a case-control study. , 2021, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[3]  G. Grasselli,et al.  The ADAMTS13‐von Willebrand factor axis in COVID‐19 patients , 2020, Journal of Thrombosis and Haemostasis.

[4]  S. Laporte,et al.  Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study , 2020, Hämostaseologie.

[5]  N. Mackman,et al.  Circulating Markers of Neutrophil Extracellular Traps Are of Prognostic Value in Patients With COVID-19 , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[6]  N. Mackman,et al.  Patients With COVID-19 Have Elevated Levels of Circulating Extracellular Vesicle Tissue Factor Activity That Is Associated With Severity and Mortality—Brief Report , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[7]  Junfeng Wang,et al.  Testing Clinical Prediction Models. , 2020, JAMA.

[8]  L. Alberio,et al.  Predicting Venous Thromboembolic Events in Patients with Coronavirus Disease 2019 Requiring Hospitalization: an Observational Retrospective Study by the COVIDIC Initiative in a Swiss University Hospital , 2020, BioMed research international.

[9]  J. Ng,et al.  COVID-19 associated coagulopathy in critically ill patients: A hypercoagulable state demonstrated by parameters of haemostasis and clot waveform analysis , 2020, Journal of Thrombosis and Thrombolysis.

[10]  R. Gooding,et al.  Lupus Anticoagulant in Patients with Covid-19. , 2020, The New England journal of medicine.

[11]  G. Lippi,et al.  Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory , 2020, Thrombosis Journal.

[12]  Shenmin Zhang,et al.  SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19 , 2020, Journal of Hematology & Oncology.

[13]  Shuohua Chen,et al.  All-cause mortality in metabolically healthy individuals was not predicted by overweight and obesity , 2020, JCI Insight.

[14]  L. Papazian,et al.  Circulating Endothelial Cells as a Marker of Endothelial Injury in Severe COVID -19 , 2020, The Journal of infectious diseases.

[15]  L. Argaud,et al.  Hypofibrinolytic state and high thrombin generation may play a major role in SARS‐COV2 associated thrombosis , 2020, Journal of Thrombosis and Haemostasis.

[16]  Kipp W. Johnson,et al.  Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection , 2020, Journal of the American College of Cardiology.

[17]  X. Cui,et al.  Risk of venous thromboembolism associated with totally implantable venous access ports in cancer patients: A systematic review and meta‐analysis , 2020, Journal of thrombosis and haemostasis : JTH.

[18]  V. Fuster,et al.  Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19 , 2020, Journal of the American College of Cardiology.

[19]  S. Sivapalaratnam,et al.  Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19 , 2020, The New England journal of medicine.

[20]  R. Woods,et al.  Neutrophil extracellular traps in COVID-19. , 2020, JCI insight.

[21]  Nils Kucher,et al.  Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy , 2020, Thrombosis Research.

[22]  Holger Moch,et al.  Endothelial cell infection and endotheliitis in COVID-19 , 2020, The Lancet.

[23]  G. Grasselli,et al.  Hypercoagulability of COVID‐19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis , 2020, Journal of Thrombosis and Haemostasis.

[24]  Theodora Psaltopoulou,et al.  Hematological findings and complications of COVID‐19 , 2020, American journal of hematology.

[25]  Feng Wang,et al.  Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.

[26]  J. Low,et al.  Critically ill COVID‐19 infected patients exhibit increased clot waveform analysis parameters consistent with hypercoagulability , 2020, American journal of hematology.

[27]  Dengju Li,et al.  Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy , 2020, Journal of Thrombosis and Haemostasis.

[28]  A. Falanga,et al.  ISTH interim guidance on recognition and management of coagulopathy in COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[29]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[30]  Dengju Li,et al.  Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.

[31]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[32]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[33]  S. Cao,et al.  Antigenic and Pathogenic Characteristics of QX-Type Avian Infectious Bronchitis Virus Strains Isolated in Southwestern China , 2019, Viruses.

[34]  T. Iba,et al.  Usefulness of the APTT waveform for the diagnosis of DIC and prediction of the outcome or bleeding risk , 2019, Thrombosis Journal.

[35]  J. Chan,et al.  Characterization of the Lipidomic Profile of Human Coronavirus-Infected Cells: Implications for Lipid Metabolism Remodeling upon Coronavirus Replication , 2019, Viruses.

[36]  Y. Abe,et al.  An Evaluation of the Activated Partial Thromboplastin Time Waveform , 2018, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[37]  F. Depasse,et al.  Clot waveform analysis: Where do we stand in 2017? , 2017, International journal of laboratory hematology.

[38]  G. Herpe,et al.  Irreversible Electroporation for Locally Advanced Pancreatic Cancer: Where Do We Stand in 2017? , 2017, Pancreas.

[39]  F. Ishida,et al.  Exogenous Magnesium Chloride Reduces the Activated Partial Thromboplastin Times of Lupus Anticoagulant-Positive Patients , 2016, PloS one.

[40]  T. Doi,et al.  Usefulness of the second-derivative curve of activated partial thromboplastin time on the ACL-TOP coagulation analyzer for detecting factor deficiencies , 2015, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[41]  P. Marik,et al.  A Descriptive Study , 2015 .

[42]  Volker Huck,et al.  The various states of von Willebrand factor and their function in physiology and pathophysiology , 2014, Thrombosis and Haemostasis.

[43]  C. Solano,et al.  A study of atypical APTT derivative curves on the ACL TOP coagulation analyser , 2011, International journal of laboratory hematology.

[44]  M. Burns,et al.  Case-Control Study , 2020, Definitions.

[45]  A. Giles,et al.  Waveform analysis of clotting test optical profiles in the diagnosis and management of disseminated intravascular coagulation (DIC). , 2002, Clinical and laboratory haematology.

[46]  J. Sixma,et al.  Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C. , 1996, Blood.

[47]  C. Kiernan.  Teachers and research in special education. , 2007, Special education: forward trends.

[48]  A. Fasanaro,et al.  [A case of hypopotassemic myopathy]. , 1981, Acta neurologica.